Tailor-made Pharma Solutions

HBW Insight : コンシューマーヘルスケア産業のニュース

CBD News Round-Up: Australia Proposes OTC Pathway, First EU Novel Food Validation, COVID Boost For UK Firm

Australia looks at switching CBD as an OTC medicine, CBDepot becomes the first European firm with an EU Novel Food validation and the UK's Vitality CBD gets a boost from the global, coronavirus-driven wellness trend.

Topic Dietary Supplements Coronavirus

HBW Insight : コンシューマーヘルスケア産業のニュース

IFRA Chair Looks Forward To Post-COVID-19 ‘Revival Of Reason’

IFRA’s new chairman Hans Holger Gliewe says one possible positive outcome of the COVID-19 pandemic could be that consumers go on putting a premium on scientific expertise after months of reliance on health experts’ advice.

Topic Coronavirus Cosmetics

Generics Bulletin: ジェネリック＆バイオシミラーニュース

Celltrion Sets Out Plans To Trial Coronavirus Treatments

In an exclusive interview with Generics Bulletin, Celltrion Healthcare’s UK commercial director, Matt Eddleston, has set out the firm’s plans to roll out an antibody test and trial two antiviral treatments for COVID-19. Meanwhile, the company’s recently-launched subcutaneous version of biosimilar infliximab, Remsima SC, is helping to free up hospital space in the UK by allowing treatment to be moved out of that setting as the coronavirus pandemic progresses.

Topic Coronavirus

HBW Insight : コンシューマーヘルスケア産業のニュース

Bayers Supplement Sales Leap By A Third On COVID Boost

Bayer posts double-digit rise in Q1 Consumer Health sales off the back of unprecedented demand for its dietary supplements in the middle of the global coronavrius pandemic. 

Topic Coronavirus

Generics Bulletin: ジェネリック＆バイオシミラーニュース

Biosimilars Conference Coverage

Industry analysts from Generics Bulletin are bringing you free insights from their comprehensive biosimilars coverage. Obtain critical industry information covering new biosimilars launches, company strategies, and new biosimilars product development.

Topic biosimilars

Generics Bulletin: ジェネリック＆バイオシミラーニュース

Celltrion Will Trial COVID-19 Antiviral From July

Celltrion has made progress in finding an effective treatment for COVID-19 by identifying 14 antibodies able to neutralize coronavirus. The company aims to eventually roll out mass production of a therapeutic antibody treatment after starting human trials this July.

Topic Coronavirus vaccines

HBW Insight : コンシューマーヘルスケア産業のニュース

‘Insufficient Evidence’ Ibuprofen Worsens COVID-19, Says UK Regulator

Review by MHRA advisory body finds no issue with ibuprofen use in COVID-19 patients and updates advice to recommend either paracetamol or ibuprofen to treat symptoms.

Topic Coronavirus

Generics Bulletin: ジェネリック＆バイオシミラーニュース

Coronavirus Puts The Brakes On Mylan-Upjohn Merger

Mylan and Pfizer’s Upjohn were all set to merge into Viatris by midway through this year, subject to certain approvals, but that will now not happen in that timeframe as the global coronavirus pandemic proves an insurmountable barrier to getting the deal over the line.  

Topic Coronavirus

Generics Bulletin: ジェネリック＆バイオシミラーニュース

Australia Relaxes Competition Rules To Facilitate Coronavirus Response

Australia’s competition regulator, the ACCC, has granted a conditional dispensation to allow generics industry association the GBMA and brand body Medicines Australia to work together to help address the coronavirus pandemic by sharing information on stock, inventory, manufacturing and the supply chain. However, tender pricing will not be among the subjects discussed.

Topic Coronavirus

Generics Bulletin: ジェネリック＆バイオシミラーニュース

Celltrion Makes Progress On Coronavirus Treatment

Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.

Topic Coronavirus

HBW Insight : コンシューマーヘルスケア産業のニュース

The Race Is On To Launch COVID-19 Antibody Home-Test In The UK

Feature: Public Health England has revealed it is only a week away from approving a COVID-19 antibody test for distribution via Amazon. HBW Insight looks at the race to place the first, government-approved coronavirus home-test on the UK market.

Topic Coronavirus

Biomedtracker: 開発中医薬品をFDA承認確率で評価, Trialtrove: 医療用医薬品の臨床試験情報デ...

COVID-19 Infographic

Access the infographic below which explores the number of treatment drugs for COVID-19 currently in clinical trials or in development, events including progress updates, partnerships, regulatory and trial announcements etc, and the number of articles published on COVID-19 as of March 3, 2020. This data has been tracked and reported via Informa Pharma Intelligence’s clinical, regulatory and commercial data and analytics, and news and insight tools including Biomedtracker, Trialtrove, Pharmaprojects, Scrip, Pink Sheet, Medtech Insight, and Generics Bulletin etc.

Topic Coronavirus

Generics Bulletin: ジェネリック＆バイオシミラーニュース

Sandoz, Teva And Mylan Step Up On Hydroxychloroquine

To meet expected demand in the weeks and months ahead, Novartis' Sandoz has committed to donate up to 130 million doses of generic hydroxychloroquine – a treatment for malaria currently under investigation as a therapy to aid in the COVID-19 pandemic – while Teva and Mylan have also made strides, as the generics industry continues to play its part in tackling the coronavirus outbreak.

Topic Coronavirus

Generics Bulletin: ジェネリック＆バイオシミラーニュース

Preserving Full Capacity Is Key To Global Coronavirus Reponse

Leaders around the world must do all they can to ensure that medicines manufacturing and the supply chain are operating at full capacity as part of efforts to tackle the coronavirus outbreak, global off-patent industry association the IGBA has urged.

Topic Coronavirus